David G Birch1, Lea D Bennett2, Jacque L Duncan3, Richard G Weleber4, Mark E Pennesi4. 1. Retina Foundation of the Southwest, Dallas, Texas; Department of Ophthalmology, UT Southwestern Medical Center, Dallas, Texas. Electronic address: dbirch@retinafoundation.org. 2. Retina Foundation of the Southwest, Dallas, Texas. 3. Department of Ophthalmology, University of California, San Francisco, California. 4. Oregon Health & Science University Casey Eye Institute, Portland, Oregon.
Abstract
PURPOSE: To evaluate the long-term efficacy of ciliary neurotrophic factor delivered via an intraocular encapsulated cell implant for the treatment of retinitis pigmentosa. DESIGN: Long-term follow-up of a multicenter, sham-controlled study. METHODS:Thirty-six patients at 3 CNTF4 sites were randomly assigned to receive a high- or low-dose implant in 1 eye and sham surgery in the fellow eye. The primary endpoint (change in visual field sensitivity at 12 months) had been reported previously. Here we measure long-term visual acuity, visual field, and optical coherence tomography (OCT) outcomes in 24 patients either retaining or explanting the device at 24 months relative to sham-treated eyes. RESULTS: Eyes retaining the implant showed significantly greater visual field loss from baseline than either explanted eyes or sham eyes through 42 months. By 60 months and continuing through 96 months, visual field loss was comparable among sham-treated eyes, eyes retaining the implant, and explanted eyes, as was visual acuity and OCT macular volume. CONCLUSIONS: Over the short term, ciliary neurotrophic factor released continuously from an intravitreal implant led to loss of total visual field sensitivity that was greater than the natural progression in the sham-treated eye. This additional loss of sensitivity related to the active implant was reversible when the implant was removed. Over the long term (60-96 months), there was no evidence of efficacy for visual acuity, visual field sensitivity, or OCT measures of retinal structure.
RCT Entities:
PURPOSE: To evaluate the long-term efficacy of ciliary neurotrophic factor delivered via an intraocular encapsulated cell implant for the treatment of retinitis pigmentosa. DESIGN: Long-term follow-up of a multicenter, sham-controlled study. METHODS: Thirty-six patients at 3 CNTF4 sites were randomly assigned to receive a high- or low-dose implant in 1 eye and sham surgery in the fellow eye. The primary endpoint (change in visual field sensitivity at 12 months) had been reported previously. Here we measure long-term visual acuity, visual field, and optical coherence tomography (OCT) outcomes in 24 patients either retaining or explanting the device at 24 months relative to sham-treated eyes. RESULTS: Eyes retaining the implant showed significantly greater visual field loss from baseline than either explanted eyes or sham eyes through 42 months. By 60 months and continuing through 96 months, visual field loss was comparable among sham-treated eyes, eyes retaining the implant, and explanted eyes, as was visual acuity and OCT macular volume. CONCLUSIONS: Over the short term, ciliary neurotrophic factor released continuously from an intravitreal implant led to loss of total visual field sensitivity that was greater than the natural progression in the sham-treated eye. This additional loss of sensitivity related to the active implant was reversible when the implant was removed. Over the long term (60-96 months), there was no evidence of efficacy for visual acuity, visual field sensitivity, or OCT measures of retinal structure.
Authors: Paul A Sieving; Rafael C Caruso; Weng Tao; Hanna R Coleman; Darby J S Thompson; Keri R Fullmer; Ronald A Bush Journal: Proc Natl Acad Sci U S A Date: 2006-02-27 Impact factor: 11.205
Authors: Michael A Sandberg; Bernard Rosner; Carol Weigel-DiFranco; Thaddeus P Dryja; Eliot L Berson Journal: Invest Ophthalmol Vis Sci Date: 2007-03 Impact factor: 4.799
Authors: Kun Do Rhee; Alberto Ruiz; Jacque L Duncan; William W Hauswirth; Matthew M Lavail; Dean Bok; Xian-Jie Yang Journal: Invest Ophthalmol Vis Sci Date: 2007-03 Impact factor: 4.799
Authors: Dean Bok; Douglas Yasumura; Michael T Matthes; Alberto Ruiz; Jacque L Duncan; Aimee V Chappelow; Sergei Zolutukhin; William Hauswirth; Matthew M LaVail Journal: Exp Eye Res Date: 2002-06 Impact factor: 3.467
Authors: William A Beltran; Qi Zhang; James W Kijas; Danian Gu; Hermann Rohrer; Julie A Jordan; Gustavo D Aguirre Journal: Invest Ophthalmol Vis Sci Date: 2003-08 Impact factor: 4.799
Authors: Biju B Thomas; Danhong Zhu; Tai-Chi Lin; Young Chang Kim; Magdalene J Seiler; Juan Carlos Martinez-Camarillo; Bin Lin; Yousuf Shad; David R Hinton; Mark S Humayun Journal: Graefes Arch Clin Exp Ophthalmol Date: 2018-09-13 Impact factor: 3.117
Authors: Songhua Li; Kota Sato; William C Gordon; Michael Sendtner; Nicolas G Bazan; Minghao Jin Journal: J Biol Chem Date: 2018-08-16 Impact factor: 5.157
Authors: David G Birch; Paul S Bernstein; Alessandro Iannacone; Mark E Pennesi; Byron L Lam; John Heckenlively; Karl Csaky; Mary Elizabeth Hartnett; Kevin L Winthrop; Thiran Jayasundera; Dianna K Hughbanks-Wheaton; Judith Warner; Paul Yang; Gary Edd Fish; Michael P Teske; Neal L Sklaver; Laura Erker; Elvira Chegarnov; Travis Smith; Aimee Wahle; Paul C VanVeldhuisen; Jennifer McCormack; Robert Lindblad; Steven Bramer; Stephen Rose; Patricia Zilliox; Peter J Francis; Richard G Weleber Journal: JAMA Ophthalmol Date: 2018-08-01 Impact factor: 7.389
Authors: Ishaq A Viringipurampeer; Cheryl Y Gregory-Evans; Andrew L Metcalfe; Emran Bashar; Orson L Moritz; Kevin Gregory-Evans Journal: Mol Neurobiol Date: 2018-06-18 Impact factor: 5.590
Authors: Jason Charish; Alireza P Shabanzadeh; Danian Chen; Patrick Mehlen; Santhosh Sethuramanujam; Hidekiyo Harada; Vera L Bonilha; Gautam Awatramani; Rod Bremner; Philippe P Monnier Journal: J Clin Invest Date: 2020-04-01 Impact factor: 14.808
Authors: Mandeep S Singh; Susanna S Park; Thomas A Albini; M Valeria Canto-Soler; Henry Klassen; Robert E MacLaren; Masayo Takahashi; Aaron Nagiel; Steven D Schwartz; Kapil Bharti Journal: Prog Retin Eye Res Date: 2019-09-05 Impact factor: 21.198